Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation

Journal of Clinical Virology

Volumn 57, Issue 1, 2013, Pages 43-49

  Göhring, Katharina ^a   Wolf, Dana ^a   Bethge, Wolfgang ^a   Mikeler, Elfriede ^a   Faul, Christoph ^a   Vogel, Wichard ^a   Vöhringer, Matthias C ^b   Jahn, Gerhard ^a   Hamprecht, Klaus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Antiviral therapy; Cytomegalovirus; Ganciclovir; Multidrug resistance; Stem cell transplantation; Viral load

Indexed keywords

CIDOFOVIR; CYCLOPHOSPHAMIDE; FLUCONAZOLE; FLUDARABINE; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MELPHALAN; PHOSPHOTRANSFERASE; THIOTEPA; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DETERIORATION; DISEASE COURSE; ENTERITIS; GASTRITIS; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KINETICS; LEUKEMIA; LUNG FIBROSIS; MALE; MORTALITY; MULTIDRUG RESISTANCE; NK T CELL LYMPHOMA; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY FAILURE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS REACTIVATION;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FATAL OUTCOME; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MUTATION; PHENOTYPE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RETROSPECTIVE STUDIES; VIRAL LOAD; VIRAL PROTEINS;

EID: 84875808590     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.01.003     Document Type: Article

References (16)

1. Baldanti F., Lurain N., Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol 2004, 65:403-409.
2. Eckle T., Prix L., Jahn G., Klingebiel T., Hangretinger R., Selle B., et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000, 96:3286-3289.
3. Limaye A.P. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Sem Respir Infect 2002, 17:265-273.
4. Gilbert C., Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005, 49:873-883.
5. Lurain N.S., Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010, 23:689-712.
6. Chevillotte M., von Einem J., Meier B.M., Lin F.M., Kestler H.A., Mertens T. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res 2010, 85:318-327.
7. Erice A., Borrell N., Li W., Miller W.J., Balfour H.H. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus isolates from bone marrow recipients with CMV disease after antiviral phrophylaxis. J Infect Dis 1998, 178:531-534.
8. Iwanesko J.M., Scott G.M., Ziegler J.B., Rawlinson W.D. Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child. J Clin Virol 2007, 40:152-155.
9. Chou S., Erice A., Jordan M.C., Vercellotti G.M., Michels K.R., Talarico C.L., et al. Analysis of UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995, 171:576-583.
10. Prix L., Hamprecht K., Holzhüter B., Hangretinger R., Klingebiel T., Jahn G. Comprehensive restriction analysis of UL97 region allows early detection of ganciclivir-resistant human cytomegalovirus in an immunocompromised child. J Infect Dis 1999, 180:491-495.
11. Göhring K., Mikeler E., Jahn G., Hamprecht K. Rapid semiquantitative real-time PCR approach for the detection of HCMV UL97 mutations conferring GCV resistance. Antivir Ther 2008, 13(3):461-466.
12. Prix L., Maierl J., Jahn G., Hamprecht K. A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains. J Clin Virol 1998, 24:29-37.
13. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008, 18:233-246.
14. Ducancelle A., Belloc S., Alain S., Scieux C., Malphettes M., Petit F., et al. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy. J Clin Virol 2004, 29:241-247.
15. Fillet A.M., Auray L., Alain S., Gourlain K., Imbert B.M., Najioullah F., et al. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. Antimicrob Agents Chemother 2004, 48:1865-1868.
16. Chou S., Lurain N.S., Weinberg A., Cai G.Y., Sharma P.L., Crumpacker C.S. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Antimicrob Agents Chemother 1999, 43:1500-1502.